<h4>Background</h4>Second-generation anaplastic lymphoma kinase (ALK) inhibitors, including alectinib and brigatinib, are widely used in patients with ALK-positive non-small cell lung cancer (NSCLC) who develop resistance or progress on crizotinib. The gene discussed is ALK; the disease is non-small cell lung carcinoma.